Tuberculosis Cell Mediated Immunity Antigen Response (T-SPOT®. TB) Test
The tuberculin skin test (TST) is the standard method in screening for latent Tuberculosis infection (LTBI) worldwide and, although the TST has good sensitivity and specificity the test may produce false positives results in patients previously vaccinated with bacilli Calmette-Guérin (BCG) or those with non-tuberculosis mycobacterial infections. The TST is easy to perform with minimal training and does not require access to laboratory facilities, however, it does require the patient to return to have the test evaluated which may be a deterrent for some patients in resource rich countries.
The T-SPOT®TB test is an alternative method to the TST in screening for LTBI in patients suspected of having latent tuberculosis Infection (LTBI). It is intended for use in conjunction with risk a of exposure assessment, clinical and/or other diagnostic evaluations. This test is an Interferon-Gamma Release Assay (IGRA) based on the in vitro detection of Interferon-gamma released by CD4+ T cells when exposed to Mycobacterium tuberculosis antigens (ESAT-6 and CFP 10). The test method utilizes an enzyme-linked immunospot (ELISPOT) method. Issues with this assay include the need to collect and handle the samples appropriately, rapid processing of the samples within 8 hours of collection, the multiple manual steps required for processing the sample in the laboratory and the relatively high cost of the test.
The disadvantage of both the TST and IGRAs is that they cannot differentiate latent tuberculosis infection (LTBI) from active tuberculosis. Diagnosis of active TB should be based on physical examination, imaging (typically a chest CT scan), sputum culture and AFB stain examination. Neither the TST nor IGRA should be used to diagnose active disease. Further both tests may have false negative results in patients who are very young (< 6 years of age), have HIV infection with low CD4 counts or are otherwise immunocompromised, patients with recent severe infections or those receiving high dose steroids or TNF inhibitors.
- Screening for Latent Mycobacterium tuberculosis infection
- Screening for Mycobacterium tuberculosis exposure and infection
Interpretation is based on amount of released IFN-g. Results are reported as positive, negative, or indeterminate and the quantitative assay measurements (Nil,TB, and Mitogen concentrations or spot counts) should be reported.
Results are reported qualitative as "Positive" or "Negative".
Negative
Whole blood collected in lithium heparin (green-top) tube. Alternatively, blood can be collected in sodium citrate (blue top tube) or sodium heparin (green top tube).
Stability
- Ambient: up 32 hours (when use TCell Xtend reagent)
- Refrigerated: not acceptable
- Frozen: not acceptable
- Lancet. 2000;356:1099-104. [PMID: 11009160]
- Clin Infect Dis. 2017 Jan 15;64(2):e1-e33. [PMID: 27932390]
- Am. J. Respir. Crit. Care Med., 2001; 163: 824-828. [PMID: 11282752]
- Nepal Med Coll J 2011; 13(4): 275-278. [PMID: 23016479]
- Infection and Immunity, 2000; 68(6): 3314-3321. [PMID: 10816479]
- Immunol 2001; 167: 5217-25. [PMID: 11673535]
- Eur Respir J. 2021 Nov 25;58(5):2100167. [PMID: 33875495]
- Infect Drug Resist. 2022 Dec 2;15:7077-7093. [PMID: 36483147]
- Respir Res. 2021 Jun 1;22(1):165. [PMID: 34074288]
- BMC Infect Dis. 2016 Jul 22;16:350. [PMID: 27450543]